Erratum to "Detection of unsuspected distant metastates and/or regional nodes by FDG-PET scan in apparent limited-disease small-cell lung cancer" [Lung Cancer 57 (2007) 328-333] (DOI:10.1016/j.lungcan.2007.04.001);Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer

Lung Cancer

Volumn 57, Issue 3, 2007, Pages 328-333

  Niho, Seiji ^a   Fujii, Hirofumi ^b   Murakami, Koji ^b,c   Nagase, Seisuke ^a   Yoh, Kiyotaka ^a   Goto, Koichi ^a   Ohmatsu, Hironobu ^a   Kubota, Kaoru ^a   Sekiguchi, Ryuzo ^a   Nawano, Shigeru ^a   Saijo, Nagahiro ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b National Cancer Center   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

CT; FDG PET; Limited disease; Occult distant metastasis; Small cell lung cancer; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DISEASE COURSE; EVALUATION; FEMALE; HUMAN; LIVER METASTASIS; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE BODY IMAGING;

EID: 34548045339     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.09.005     Document Type: Erratum

References (19)

1. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 4 (1973) 31-42
2. Takada M., Fukuoka M., Kawahara M., Sugiura T., Yokoyama A., Yokota S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20 (2002) 3054-3060
3. Turrisi III A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 265-271
4. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
5. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
6. MacManus M.P., Hicks R.J., Matthews J.P., Hogg A., McKenzie A.F., Wirth A., et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 287-293
7. 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors. Eur J Nucl Med Mol Imaging 34 (2007) 54-59
8. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 19 (2001) 111-118
9. Bradley J.D., Dehdashti F., Mintun M.A., Govindan R., Trinkaus K., and Siegel B.A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22 (2004) 3248-3254
10. 18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31 (2004) 1614-1620
11. Blum R., MacManus M.P., Rischin D., Michael M., Ball D., and Hicks R.J. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 27 (2004) 164-171
12. Chin Jr. R., McCain T.W., Miller A.A., Dunagan D.P., Acostamadiedo J., Douglas Case L., et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 37 (2002) 1-6
13. Hauber H.P., Bohuslavizki K.H., Lund C.H., Fritscher-Ravens A., Meyer A., and Pforte A. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 119 (2001) 950-954
14. 18F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44 (2003) 1911-1917
15. 18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imag 30 (2003) 78-84
16. Schumacher T., Brink I., Mix M., Reinhardt M., Herget G., Digel W., et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 28 (2001) 483-488
17. Shen Y.Y., Shiau Y.C., Wang J.J., Ho S.T., and Kao C.H. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 22 (2002) 1257-1264
18. Stahel R.A., Ginsberg R., Havemann K., Hirsch F.R., Ihde D.C., Jassem J., et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5 (1989) 119-126
19. Micke P., Faldum A., Metz T., Beeh K.M., Bittinger F., Hengstler J.G., et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer-what limits limited disease?. Lung Cancer 37 (2002) 271-276